A Phase 4 interventional study of Pioglitazone and Placebo in Bone Metabolism, sponsored by Takeda. Completed at 34 sites in United States. Open to female participants aged Up to 70 Years. Per ClinicalTrials.gov, last updated 2012-02-03.
Sponsored by Takeda · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing pioglitazone in Glucose Metabolism Disorders — none open to participants now, none under way, none of them phase 3. Pioglitazone · Glucose Metabolism Disorders.
Among the 24 studies testing pioglitazone in Glucose Metabolism Disorders, this one is the 17th largest by enrollment, is one of 4 that started in 2008, is one of 8 in phase 4, and was the 13th registered.
361 studies on the registry are indexed under Glucose Metabolism Disorders; 38 are open to participants now.
Browse Glucose Metabolism Disorders studies →None of the 24 studies testing pioglitazone in Glucose Metabolism Disorders is open now. The open studies under Glucose Metabolism Disorders, anywhere →
Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 29 Glucose Metabolism Disorders studies recruiting now, 9 (31%) set no upper age limit and 18 (62%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: Up to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 156 is above the median of 60 across 308 interventional studies indexed under Glucose Metabolism Disorders.
Median enrollment 318 across the 24 interventional studies. Of the 23 that completed or were terminated, 5 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 24 have an industry lead sponsor. The 4 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
41 studies in Glucose Metabolism Disorders by Takeda: none open now, none under way, none of them phase 3. Of 41 finished, 15 (37%) have results posted.
Among the 41 studies in Glucose Metabolism Disorders by Takeda, this one is the 31st largest by enrollment of the 40 interventional ones that give a count, is one of 5 that started in 2008, is one of 6 in phase 4, and was the 21st registered.
Takeda’s Glucose Metabolism Disorders studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing pioglitazone in Glucose Metabolism Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 41 in Glucose Metabolism Disorders:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of pioglitazone on bone metabolism in postmenopausal women with impaired fasting glucose.
The World Health Organization has estimated that 30% of all women aged over 50 years (postmenopausal) have osteoporosis according to a definition of Bone Mineral Density at any site being more than 2.5 standard deviations below the mean for young healthy adult women.
A known risk factor for development of osteoporosis and fracture is diabetes mellitus, with correlations to duration of disease and poor glycemic control.
Pioglitazone is a thiazolidinedione developed by Takeda Pharmaceuticals for the treatment of type 2 diabetes. Preclinical studies to date on the bone effects of thiazolidinediones have not clearly identified a mechanism of bone loss. While there is evidence of increased bone fractures in postmenopausal diabetic females treated with a thiazolidinedione, the mechanism is not known. Initial studies with thiazolidinediones in humans have focused on short term exposure (12 to 14 weeks) and non-diabetic females. These studies have shown acute changes in circulating bone markers and bone density, but have been questioned because they may not represent bone metabolism in states of abnormal glucose metabolism. Impaired glucose tolerance has been identified not only as a risk factor for developing type 2 diabetes, but also at higher risk for known complications of diabetes. Examination of the effect of thiazolidinediones on bone metabolism in IGT patients will provide data in patients with abnormal glucose tolerance, but without the potential confounding effects of oral hypoglycemic medications to treat type 2 diabetes.
The primary objective of this study is to evaluate the effect of pioglitazone on bone mass and metabolism in postmenopausal women with impaired fasting glucose or impaired glucose tolerance. Total participation time in this study is approximately 1 year and six months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has any of the following disorders:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pioglitazone
Drug: Placebo
Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.
Also known as: ACTOS®
Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
Also known as: ACTOS®
Percent Change From Baseline to Month 12 in Bone Mineral Density in the Total Proximal Femur by Dual-Energy-Ray Absorptiometry (DXA)
The change in bone mineral density in the total proximal femur at month 12 relative to baseline. DXA is a means of measuring BMD through x-ray.
Time frame: Baseline and Month 12.
Percent Change From Month 12 to Month 18 in Bone Mineral Density in the Total Proximal Femur by DXA
The change in bone mineral density in the total proximal femur at month 18 relative to month 12. DXA is a means of measuring BMD through x-ray.
Time frame: Month 12 and Month 18.
Change in Fasting Plasma Glucose (FPG)
The change between the fasting plasma glucose value collected at each time frame indicated.
Time frame: Baseline and Month 12; Month 12 and Month 18.
Number of Participants Who Converted to Type 2 Diabetes Mellitus (T2DM)
Participants were considered to have converted to T2DM if there were ≥2 consecutive post-Baseline FPG measurements ≥126 mg/dL. Participants meeting criteria were tabulated and summarized by Study Period (Treatment and Follow-up). Conversion to T2DM during Treatment Period occurred if either both of the consecutive post-Baseline high FPG values, or the first of the 2 consecutive high values occurred on or before the first day off study drug. Conversion to T2DM occurred during the Follow-up Period if both consecutive high values occurred after at least 1 day after the Treatment Period.
Time frame: Up to 18 months.
Number of Participants With Fracture
Number of participants with confirmed (through an adjudication process) fractures during the study. Circumstances surrounding the fracture, available X-ray and other diagnostic results and healing status were collected for the adjudication process.
Time frame: Up to 18 months.
Participants took part in the study at 25 investigative sites in the United States from 23 May 2008 to 02 February 2011.
| Milestone | Pioglitazone | Placebo |
|---|---|---|
| Started | 78 | 78 |
| Completed | 60 | 57 |
| Not completed | 18 | 21 |
| Withdrew: Adverse event | 4 | 5 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Lost to follow-up | 5 | 3 |
| Withdrew: Withdrawal by subject | 5 | 7 |
| Withdrew: Bmd loss >7% | 2 | 3 |
The change in bone mineral density in the total proximal femur at month 12 relative to baseline. DXA is a means of measuring BMD through x-ray.
| percent | Pioglitazone | Placebo |
|---|---|---|
| Percent Change From Baseline to Month 12 in Bone Mineral Density in the Total Proximal Femur by Dual-Energy-Ray Absorptiometry (DXA) | -0.69 ± 0.284 | -0.14 ± 0.277 |
The change in bone mineral density in the total proximal femur at month 18 relative to month 12. DXA is a means of measuring BMD through x-ray.
| percent | Pioglitazone | Placebo |
|---|---|---|
| Percent Change From Month 12 to Month 18 in Bone Mineral Density in the Total Proximal Femur by DXA | -0.14 ± 0.265 | 0.04 ± 0.258 |
The change between the fasting plasma glucose value collected at each time frame indicated.
| mg/dL | Pioglitazone | Placebo |
|---|---|---|
| Baseline to Month 12 (n=57; n=61) | -2.8 ± 1.66 | 6.0 ± 1.61 |
| Month 12 to Month 18 (n=54; n=57) | 0.4 ± 2.00 | -1.0 ± 1.94 |
Participants were considered to have converted to T2DM if there were ≥2 consecutive post-Baseline FPG measurements ≥126 mg/dL. Participants meeting criteria were tabulated and summarized by Study Period (Treatment and Follow-up). Conversion to T2DM during Treatment Period occurred if either both of the consecutive post-Baseline high FPG values, or the first of the 2 consecutive high values occurred on or before the first day off study drug. Conversion to T2DM occurred during the Follow-up Period if both consecutive high values occurred after at least 1 day after the Treatment Period.
| participants | Pioglitazone | Placebo |
|---|---|---|
| Double-Blind Period (n=76; n=75) | 1 ± 1.3 | 7 ± 9.3 |
| Follow-up Period (n=63; n=59) | 0 ± 0.0 | 1 ± 1.7 |
Number of participants with confirmed (through an adjudication process) fractures during the study. Circumstances surrounding the fracture, available X-ray and other diagnostic results and healing status were collected for the adjudication process.
| participants | Pioglitazone | Placebo |
|---|---|---|
| Number of Participants With Fracture | 1 | 3 |
Collected over Treatment-emergent serious adverse events are serious adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pioglitazone | — | 3/78 (3.8%) | 32/78 (41%) |
| Placebo | — | 1/78 (1.3%) | 34/78 (43.6%) |
| Event | Pioglitazone | Placebo |
|---|---|---|
| Cardiac failure congestiveCardiac disorders | 1/78 | 0/78 |
| DiverticulitisInfections and infestations | 1/78 | 0/78 |
| Peridiverticular abscessInfections and infestations | 1/78 | 0/78 |
| TracheobronchitisInfections and infestations | 0/78 | 1/78 |
| Subdural haematomaInjury, poisoning and procedural complications | 1/78 | 0/78 |
| MigraineNervous system disorders | 1/78 | 0/78 |
| Calculus urinaryRenal and urinary disorders | 0/78 | 1/78 |
| Event | Pioglitazone | Placebo |
|---|---|---|
| Urinary tract infectionInfections and infestations | 6/78 | 10/78 |
| Oedema peripheralGeneral disorders | 9/78 | 2/78 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/78 | 4/78 |
| SinusitisInfections and infestations | 0/78 | 6/78 |
| Back painMusculoskeletal and connective tissue disorders | 4/78 | 5/78 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/78 | 0/78 |
| Blood glucose increasedInvestigations | 1/78 | 4/78 |
| Blood parathyroid hormone increasedInvestigations | 4/78 | 1/78 |
| FallInjury, poisoning and procedural complications | 2/78 | 4/78 |
| HeadacheNervous system disorders | 2/78 | 4/78 |
| Age Continuous(years) | Pioglitazone | Placebo | Total |
|---|---|---|---|
| Mean | 59.0 ± 5.04 | 60.2 ± 6.17 | 59.6 ± 5.65 |
| Age, Customized(participants) | Pioglitazone | Placebo | Total |
|---|---|---|---|
| <45 years | 0 | 1 | 1 |
| Between 45 and 64 years | 66 | 54 | 120 |
| ≥65 years | 12 | 23 | 35 |
| Sex: Female, Male(Participants) | Pioglitazone | Placebo | Total |
|---|---|---|---|
| Female | 78 | 78 | 156 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(participants) | Pioglitazone | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 2 | 4 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 6 | 12 |
| White | 70 | 68 | 138 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Pioglitazone | Placebo | Total |
|---|---|---|---|
| United States | 78 | 78 | 156 |
| Ethnicity(participants) | Pioglitazone | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 38 | 34 | 72 |
| Non Hispanic or Latino | 40 | 44 | 84 |
| Height(cm) | Pioglitazone | Placebo | Total |
|---|---|---|---|
| Mean | 160.3 ± 6.85 | 161.1 ± 7.70 | 160.7 ± 7.28 |
| Weight(kg) | Pioglitazone | Placebo | Total |
|---|---|---|---|
| Mean | 76.03 ± 13.406 | 79.02 ± 16.326 | 77.53 ± 14.964 |
3 further baseline measures are reported on the registry.
The record gives a start of May 2008, a primary completion of Jan 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pioglitazone
Glucose Metabolism Disorders →